FDA Clears Faster Versions of AdvanDx Bloodstream Pathogen Tests | GenomeWeb

NEW YORK (GenomeWeb News) – Molecular diagnostics firm AdvanDx said today that it has received 510(k) clearance from the US Food and Drug Administration for faster versions of its Escherichia coli/Pseudomonas aeruginosa and EK/P. aeruginosa diagnostic tests.

The new versions of the tests, which use peptide nucleic acid fluorescence in situ hybridization, or PNA FISH, provide results in 90 minutes instead of 2.5 hours for conventional tests because PNA probe hybridization is reduced from 90 minutes to 30 minutes, AdvanDx said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.